Global Bioengineered protein drugs Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Bioengineered proteins, which serve as potent therapeutic proteins, are created to be essential participants in all biological processes. These unique medications are attracting interest from the pharmaceutical industry due to their specificity, safety, bio reactivity, and success rate in treating serious illnesses and injuries. Drugs made from bioengineered proteins are key players in the biological process and the development of effective therapeutics. The medication made from bioengineered proteins contains a variety of items, including hormones, vaccines, cytokines, and monoclonal antibodies. The Bioengineered protein drugs market is expanding because of factors such as rising prevelance of various diseases such as cancer, diabetes and other diseases as well as rising development of personalized medicine.
Rising prevelance of cancer globally is fostering the market growth, , according to estimates from the International Agency for Research on Cancer (IARC), there were 17.0 million new instances of cancer and 9.5 million cancer-related deaths in 2018 and it is estimated increase to 27.5 million new cases by 2040. One of the chronic diseases with the quickest rate of growth is diabetes. In recent decades, its prevalence has steadily increased. The World Health Organization projects that by 2021, diabetes will affect 537 million individuals worldwide, with one in ten developing other forms of the disease. Moreover, populations that are elderly and fat are more likely to develop chronic diseases. The World Bank Group estimates that there were 727 million senior citizens worldwide in 2020, and that number will triple over the next three decades, reaching 1.5 billion by 2050. In addition, rising drug discovery activities, and rising healthcare research and development activities in the region is fostering the market growth. However, the high cost of Bioengineered protein drugs stifles market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Bioengineered protein drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the dominance of branded products and the region's increasing disease prevalence. Whereas Asia Pacific is expected to grow with a highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, an increase in the number of collaborations for product development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.
Major market players included in this report are:
- Abbott Laboratories
- Amgen
- Baxter Healthcare
- Bayer Healthcare Pharmaceuticals
- Eli Lilly And Co.
- GlaxoSmithKline
- Hoffman-la-Roche
- Johnson And Johnson
- Merck And Co. Inc.,
- Fresenius Kabi USA
Recent Developments in the Market:
- In April 2022, Satellite Bio introduces a fresh method for creating tissues using bioengineering. This company has expertise in synthetic biology, regenerative medicine, cell therapy, cell biology, and tissue engineering.
- In January 2022, A new biotechnology company named Altos Laboratories was founded with the goal of deciphering the intricate biology underlying the cellular renewal programming.
Global Bioengineered protein drugs Market Report Scope:
- Historical Data: 2019-2020-2021
- Base Year for Estimation: 2021
- Forecast period: 2022-2029
- Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
- Segments Covered: Drug Type, Diseases, Technology, Drug Delivery Methods, Region
- Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
- Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Drug Typeofferings of key players. The detailed segments and sub-segment of the market are explained below.
By Drug Type:
- Recombinant Protein Drugs
- Peptide Hormones
- Vaccines
- Therapeutic Enzymes
- Monoclonal Antibodies
- Cytokines
- Others
By Disease:
- Diabetes
- Cancer
- Skin Diseases
- Blood disorders
- Heart Diseases
- Neurodegenerative Diseases
- Others
By Technology:
- Fractionation
- Bioreactors And Microbial Cell Fermentation
- Genetic Engineering
- Genetically Modified Organisms
- Pharming
- Others
By Region:
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Latin America
- Brazil
- Mexico
- RoLA
- Rest of the World
Table of Contents
Chapter 1. Executive Summary
- 1.1. Market Snapshot
- 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
- 1.2.1. Bioengineered protein drugs Market, by Region, 2019-2029 (USD Billion)
- 1.2.2. Bioengineered protein drugs Market, by Drug Type, 2019-2029 (USD Billion)
- 1.2.3. Bioengineered protein drugs Market, by Diseases, 2019-2029 (USD Billion)
- 1.2.4. Bioengineered protein drugs Market, by Technology, 2019-2029 (USD Billion)
- 1.2.5. Bioengineered protein drugs Market, by Drug Delivery Method, 2019-2029 (USD Billion)
- 1.3. Key Trends
- 1.4. Estimation Methodology
- 1.5. Research Assumption
Chapter 2. Global Bioengineered protein drugs Market Definition and Scope
- 2.1. Objective of the Study
- 2.2. Market Definition & Scope
- 2.2.1. Scope of the Study
- 2.2.2. Industry Evolution
- 2.3. Years Considered for the Study
- 2.4. Currency Conversion Rates
Chapter 3. Global Bioengineered protein drugs Market Dynamics
- 3.1. Bioengineered protein drugs Market Impact Analysis (2019-2029)
- 3.1.1. Market Drivers
- 3.1.1.1. Increasing prevelance of various diseases such as cancer and diabetes
- 3.1.1.2. Growing development of personalised medicine
- 3.1.2. Market Challenges
- 3.1.2.1. High Cost of Bioengineered protein drugs
- 3.1.3. Market Opportunities
- 3.1.3.1. Advancements in Formulation
Chapter 4. Global Bioengineered protein drugs Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
- 4.3. PEST Analysis
- 4.3.1. Political
- 4.3.2. Economical
- 4.3.3. Social
- 4.3.4. Technological
- 4.4. Top investment opportunity
- 4.5. Top winning strategies
- 4.6. Industry Experts Prospective
- 4.7. Analyst Recommendation & Conclusion
Chapter 5. Risk Assessment: COVID-19 Impact
- 5.1. Assessment of the overall impact of COVID-19 on the industry
- 5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Bioengineered protein drugs Market, by Drug Type
- 6.1. Market Snapshot
- 6.2. Global Bioengineered protein drugs Market by Drug Type, Performance - Potential Analysis
- 6.3. Global Bioengineered protein drugs Market Estimates & Forecasts by Drug Type 2019-2029 (USD Billion)
- 6.4. Bioengineered protein drugs Market, Sub Segment Analysis
- 6.4.1. Recombinant Protein Drugs
- 6.4.2. Peptide Hormones
- 6.4.3. Vaccines
- 6.4.4. Therapeutic Enzymes
- 6.4.5. Monoclonal Antibodies
- 6.4.6. Cytokines
- 6.4.7. Others
Chapter 7. Global Bioengineered protein drugs Market, by Diseases
- 7.1. Market Snapshot
- 7.2. Global Bioengineered protein drugs Market by Diseases, Performance - Potential Analysis
- 7.3. Global Bioengineered protein drugs Market Estimates & Forecasts by Diseases 2019-2029 (USD Billion)
- 7.4. Bioengineered protein drugs Market, Sub Segment Analysis
- 7.4.1. Diabetes
- 7.4.2. Cancer
- 7.4.3. Skin Diseases
- 7.4.4. Blood disorders
- 7.4.5. Heart Diseases
- 7.4.6. Neurodegenerative Diseases
- 7.4.7. Others
Chapter 8. Global Bioengineered protein drugs Market, by Technology
- 8.1. Market Snapshot
- 8.2. Global Bioengineered protein drugs Market by Technology, Performance - Potential Analysis
- 8.3. Global Bioengineered protein drugs Market Estimates & Forecasts by Technology 2019-2029 (USD Billion)
- 8.4. Bioengineered protein drugs Market, Sub Segment Analysis
- 8.4.1. Fractionation
- 8.4.2. Bioreactors And Microbial Cell Fermentation
- 8.4.3. Genetic Engineering
- 8.4.4. Genetically Modified Organisms
- 8.4.5. Pharming
- 8.4.6. Others
Chapter 9. Global Bioengineered protein drugs Market, by Drug Delivery Method
- 9.1. Market Snapshot
- 9.2. Global Bioengineered protein drugs Market by Drug Delivery Method, Performance - Potential Analysis
- 9.3. Global Bioengineered protein drugs Market Estimates & Forecasts by Drug Delivery Method 2019-2029 (USD Billion)
- 9.4. Bioengineered protein drugs Market, Sub Segment Analysis
- 9.4.1. Traditional Methods
- 9.4.2. Novel approaches according to recent research
Chapter 10. Global Bioengineered protein drugs Market, Regional Analysis
- 10.1. Bioengineered protein drugs Market, Regional Market Snapshot
- 10.2. North America Bioengineered protein drugs Market
- 10.2.1. U.S. Bioengineered protein drugs Market
- 10.2.1.1. Drug Type breakdown estimates & forecasts, 2019-2029
- 10.2.1.2. Diseases breakdown estimates & forecasts, 2019-2029
- 10.2.1.3. Technology breakdown estimates & forecasts, 2019-2029
- 10.2.1.4. Drug Delivery Method breakdown estimates & forecasts, 2019-2029
- 10.2.2. Canada Bioengineered protein drugs Market
- 10.3. Europe Bioengineered protein drugs Market Snapshot
- 10.3.1. U.K. Bioengineered protein drugs Market
- 10.3.2. Germany Bioengineered protein drugs Market
- 10.3.3. France Bioengineered protein drugs Market
- 10.3.4. Spain Bioengineered protein drugs Market
- 10.3.5. Italy Bioengineered protein drugs Market
- 10.3.6. Rest of Europe Bioengineered protein drugs Market
- 10.4. Asia-Pacific Bioengineered protein drugs Market Snapshot
- 10.4.1. China Bioengineered protein drugs Market
- 10.4.2. India Bioengineered protein drugs Market
- 10.4.3. Japan Bioengineered protein drugs Market
- 10.4.4. Australia Bioengineered protein drugs Market
- 10.4.5. South Korea Bioengineered protein drugs Market
- 10.4.6. Rest of Asia Pacific Bioengineered protein drugs Market
- 10.5. Latin America Bioengineered protein drugs Market Snapshot
- 10.5.1. Brazil Bioengineered protein drugs Market
- 10.5.2. Mexico Bioengineered protein drugs Market
- 10.5.3. Rest of Latin America Bioengineered protein drugs Market
- 10.6. Rest of The World Bioengineered protein drugs Market
Chapter 11. Competitive Intelligence
- 11.1. Top Market Strategies
- 11.2. Company Profiles
- 11.2.1. Abbott Laboratories
- 11.2.1.1. Key Information
- 11.2.1.2. Overview
- 11.2.1.3. Financial (Subject to Data Availability)
- 11.2.1.4. Product Summary
- 11.2.1.5. Recent Developments
- 11.2.2. Amgen
- 11.2.3. Baxter Healthcare
- 11.2.4. Bayer Healthcare Pharmaceuticals
- 11.2.5. Eli Lilly And Co.
- 11.2.6. GlaxoSmithKline
- 11.2.7. Hoffman-la-Roche
- 11.2.8. Johnson And Johnson
- 11.2.9. Merck And Co. Inc.,
- 11.2.10. Fresenius Kabi USA
Chapter 12. Research Process
- 12.1. Research Process
- 12.1.1. Data Mining
- 12.1.2. Analysis
- 12.1.3. Market Estimation
- 12.1.4. Validation
- 12.1.5. Publishing
- 12.2. Research Attributes
- 12.3. Research Assumption